A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).

Authors: James Isaacs, Lucy Boyce Kennedy, Anthony P. Tufaro, Mark D. DeLacure, Anthony Visioni, Eren Berber, Daniel Raymond, Paolo Fabrizio Caimi, John C. Molina, Yee Peng Phoon, Joshua Arbesman, Jennifer S. Ko, Jan Joseph Melenhorst, Joseph J. Skitzki, Craig Steven Sauter, Brian Gastman, Thach-Giao Truong

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9611

Source: Full article

---

Abstract

TPS9611